IMpower010: Phase III Study of Atezolizumab vs BSC After Adjuvant Chemotherapy in Patients with Completely Resected NSCLC

被引：3
|
作者：
Vallieres, Eric [1 ]
Felip, Enriqueta [2 ]
Altorki, Nasser [3 ]
Zhou, Caicun [4 ]
Zuo, Yunxia [5 ]
Howland, Michael [6 ]
Xia, Fan [5 ]
Hoang, Tien [6 ]
Sandler, Alan [6 ]
Wakelee, Heather [7 ]
机构：
[1] Swedish Canc Inst, Seattle, WA USA
[2] Vall dHebron Univ Hosp, Barcelona, Spain
[3] New York Presbyterian Hosp, Weill Cornell Med, New York, NY USA
[4] Tongji Univ, Affiliated Shanghai Pulm Hosp, Shanghai, Peoples R China
[5] Roche China Holding Ltd, Shanghai, Peoples R China
[6] Genentech Inc, San Francisco, CA 94080 USA
[7] Stanford Canc Inst, Stanford, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2016年 / 11卷 / 11期
关键词：
D O I：
10.1016/j.jtho.2016.09.090
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS01.55
引用
收藏
页码：S304 / S304
页数：1
相关论文
共 50 条
  • [1] IMpower010: Phase III Study of Atezolizumab vs BSC after Adjuvant Chemotherapy in Patients with Completely Resected NSCLC
    Wakelee, Heather
    Altorki, Nasser
    Vallieres, Eric
    Zhou, Caicun
    Zuo, Yunxia
    Howland, Michael
    Xia, Fan
    Hoang, Tien
    Sandler, Alan
    Felip, Enriqueta
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1305 - S1305
  • [2] IMpower010: A Phase III Study of Atezolizumab vs Best Supportive Care Following Adjuvant Chemotherapy in Completely Resected NSCLC
    Felip, E.
    Wakelee, H.
    Vallieres, E.
    Zhou, C.
    Zuo, Y.
    Xia, F.
    Sandler, A.
    Altorki, N.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2398 - S2399
  • [3] IMpower010: A Phase III trial investigating atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy (chemo) in patients (pts) with completely resected NSCLC
    Zhou, C.
    Altorki, N.
    Vallieres, E.
    Felip, E.
    Zuo, Y.
    Howland, M.
    Xia, F.
    Hoang, T.
    Sandler, A.
    Wakelee, H.
    ANNALS OF ONCOLOGY, 2016, 27
  • [4] A phase III trial to compare atezolizumab (atezo) vs best supportive care (BSC) following adjuvant chemotherapy in patients (pts) with completely resected NSCLC: IMpower010.
    Wakelee, Heather A.
    Altorki, Nasser K.
    Vallieres, Eric
    Zhou, Caicun
    Zuo, Yunxia
    Howland, Michael
    Xia, Fan
    Sandler, Alan
    Felip, Enriqueta
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] IMpower010:Overall Survival Interim Analysis of a Phase III Study of Atezolizumab vs Best Supportive Care in Resected NSCLC
    Wakelee, H.
    Altorki, N.
    Felip, E.
    Vallieres, E.
    Vynnychenko, I. O.
    Akopov, A.
    Martinez-Marti, A.
    Chella, A.
    Bondarenko, I.
    Sugawara, S.
    Fan, Y.
    Kenmotsu, H.
    Chen, Y. -M.
    Deng, Y.
    Wu, F.
    McNally, V.
    Bennett, E.
    Gitlitz, B. J.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S2 - S2
  • [6] IMpower010: results from Asian patients in a phase 3 study of adjuvant atezolizumab in resected stage IB-IIIA NSCLC
    Kenmotsu, Hirotsugu
    Zhou, Caicun
    Altorki, Nasser
    Felip, Enriqueta
    Vallieres, Eric
    Sugawara, Shunichi
    Sakai, Hiroshi
    Saito, Haruhiro
    Tao, Min
    Kawaguchi, Koji
    Liu, Yunpeng
    Yu, Chong-Jen
    Wu, Qiong
    Lin, Huang
    Wu, Fan
    Bennett, Elizabeth
    Mcnally, Virginia
    Gitlitz, Barbara
    Wakelee, Heather
    ANNALS OF ONCOLOGY, 2022, 33 : S464 - S464
  • [7] IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC
    Zhou, C.
    Das Thakur, M.
    Srivastava, M. K.
    Zou, W.
    Xu, H.
    Ballinger, M.
    Felip, E.
    Wakelee, H.
    Altorki, N. K.
    Reck, M.
    Liersch, R.
    Kryzhanivska, A.
    Harada, M.
    Tanaka, H.
    Hamm, J.
    McCune, S.
    McNally, V.
    Bennett, E.
    Gitlitz, B.
    Novello, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1374 - S1374
  • [8] IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC
    Felip, E.
    Vallieres, E.
    Zhou, C.
    Wakelee, H.
    Bondarenko, I.
    Sakai, H.
    Saito, H.
    Ursol, G.
    Kawaguchi, K.
    Liu, Y.
    Levchenko, E.
    Kislov, N.
    Reck, M.
    Liersch, R.
    McNally, V. A.
    Zhu, Q.
    Ding, B.
    Bennett, E.
    Gitlitz, B.
    Altorki, N. K.
    ANNALS OF ONCOLOGY, 2021, 32 : S1319 - S1319
  • [9] IMpower010: Updated overall survival and safety results from Asian patients in a Phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA NSCLC
    Wang, Jie
    Fan, Yun
    Fang, Jian
    He, Jianxing
    Liu, Yunpeng
    Tao, Min
    Altorki, Nasser
    Felip, Enriqueta
    Wakelee, Heather
    Vallieres, Eric
    Belleli, Rossella
    McNally, Virginia
    Bennett, Elizabeth
    Gitlitz, Barbara J.
    Zhou, Caicun
    CANCER RESEARCH, 2024, 84 (07)
  • [10] IMpower010 5-y Subgroup Analysis and Relapse Patterns: Phase 3 Study of Atezolizumab vs BSC in Stage II-IIIA NSCLC
    Felip, E.
    Wakelee, H. A.
    Vallieres, E.
    Martinez-Marti, A.
    Goloborodko, O.
    Zhou, C.
    Rittmeyer, A.
    Chella, A.
    Reck, M.
    Csoszi, T.
    Bondarenko, I.
    Kenmotsu, H.
    Schutte, W.
    Ding, B.
    Zhu, Q.
    Ballinger, M.
    Bennett, E.
    Gitlitz, B. J.
    Altorki, N.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S8 - S9
12345